CK2-mediated Hyperphosphorylation of Topoisomerase I Targets Serine 506, Enhances Topoisomerase I-DNA Binding, and Increases Cellular Camptothecin Sensitivity

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Nov 28

PMID 23185622

Citations 15

Authors

Keya Bandyopadhyay

Pingchuan Li

Ruth A Gjerset

Affiliations

Soon will be listed here.

Abstract

Topoisomerase I is the target for a potent class of chemotherapeutic drugs derived from the plant alkaloid camptothecin that includes irinotecan and topotecan. In this study we have identified a novel site of CK2-mediated topoisomerase I (topo I) phosphorylation at serine 506 (PS506) that is relevant to topo I function and to cellular responses to these topo I-targeted drugs. CK2 treatment induced hyperphosphorylation of recombinant topo I and expression of the PS506 epitope, and resulted in increased binding of topo I to supercoiled plasmid DNA. Hyperphosphorylated topo I was approximately three times more effective than the basal phosphorylated enzyme at relaxing plasmid supercoils but had similar DNA cleavage activity once bound to DNA. The PS506 epitope was expressed in cancer cell lines with elevated CK2 activity, hyperphosphorylated topo I, and increased sensitivity to camptothecin. In contrast, PS506 was not detected in normal cells or cancer cell lines with lower levels of CK2 activity. By experimentally manipulating CK2 activity in cancer cell lines, we demonstrate a cause and effect relationship between CK2 activity, PS506 expression, camptothecin-induced cellular DNA damage, and cellular camptothecin sensitivity. Our results show that the PS506 epitope is an indicator of dysregulated, hyperphosphorylated topo I in cancer cells, and may thus serve as a diagnostic or prognostic biomarker and predict tumor responsiveness to widely used topo I-targeted therapies.

Citing Articles

CK2 activity is crucial for proper glucagon expression.

Ampofo E, Pack M, Wrublewsky S, Boewe A, Spigelman A, Koch H Diabetologia. 2024; 67(7):1368-1385.

PMID: 38503901 PMC: 11153270. DOI: 10.1007/s00125-024-06128-1.

Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma.

Boewe A, Wemmert S, Kulas P, Schick B, Gotz C, Wrublewsky S Biomedicines. 2022; 10(5).

PMID: 35625703 PMC: 9138789. DOI: 10.3390/biomedicines10050966.

Different Camptothecin Sensitivities in Subpopulations of Colon Cancer Cells Correlate with Expression of Different Phospho-Isoforms of Topoisomerase I with Different Activities.

Tesauro C, Keller J, Gromova I, Gromov P, Frohlich R, Erlandsen J Cancers (Basel). 2020; 12(5).

PMID: 32423158 PMC: 7281652. DOI: 10.3390/cancers12051240.

Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.

Bjornsti M, Kaufmann S F1000Res. 2019; 8.

PMID: 31602296 PMC: 6774054. DOI: 10.12688/f1000research.20201.1.

Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents.

Wang W, Rodriguez-Silva M, Acanda de la Rocha A, Wolf A, Lai Y, Liu Y Cancers (Basel). 2019; 11(10).

PMID: 31547492 PMC: 6827102. DOI: 10.3390/cancers11101416.

References

Olnes M, Kurl R . Isolation of nuclear extracts from fragile cells: a simplified procedure applied to thymocytes. Biotechniques. 1994; 17(5):828-9. View

Shuman S . Vaccinia DNA topoisomerase I promotes illegitimate recombination in Escherichia coli. Proc Natl Acad Sci U S A. 1989; 86(10):3489-93. PMC: 287163. DOI: 10.1073/pnas.86.10.3489. View

Redinbo M, Stewart L, Kuhn P, Champoux J, Hol W . Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 1998; 279(5356):1504-13. DOI: 10.1126/science.279.5356.1504. View

Arlt M, Glover T . Inhibition of topoisomerase I prevents chromosome breakage at common fragile sites. DNA Repair (Amst). 2010; 9(6):678-89. PMC: 2896008. DOI: 10.1016/j.dnarep.2010.03.005. View

Stalter G, Siemer S, Becht E, Ziegler M, Remberger K, Issinger O . Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochem Biophys Res Commun. 1994; 202(1):141-7. DOI: 10.1006/bbrc.1994.1904. View

Shevchenko A, Wilm M, Vorm O, Mann M . Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996; 68(5):850-8. DOI: 10.1021/ac950914h. View

Turman M, Douvas A . A casein kinase type II (CKII)-like nuclear protein kinase associates with, phosphorylates, and activates topoisomerase I. Biochem Med Metab Biol. 1993; 50(2):210-25. DOI: 10.1006/bmmb.1993.1063. View

Liu L . DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989; 58:351-75. DOI: 10.1146/annurev.bi.58.070189.002031. View

Pommier Y, Pourquier P, Fan Y, Strumberg D . Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta. 1998; 1400(1-3):83-105. DOI: 10.1016/s0167-4781(98)00129-8. View

10.

Bandyopadhyay K, Lee C, Haghighi A, Baneres J, Parello J, Gjerset R . Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor. Biochemistry. 2007; 46(49):14325-34. DOI: 10.1021/bi7013618. View

11.

Rogakou E, Boon C, Redon C, Bonner W . Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol. 1999; 146(5):905-16. PMC: 2169482. DOI: 10.1083/jcb.146.5.905. View

12.

Zhu J, Schiestl R . Topoisomerase I involvement in illegitimate recombination in Saccharomyces cerevisiae. Mol Cell Biol. 1996; 16(4):1805-12. PMC: 231167. DOI: 10.1128/MCB.16.4.1805. View

13.

Trembley J, Wang G, Unger G, Slaton J, Ahmed K . Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci. 2009; 66(11-12):1858-67. PMC: 4385580. DOI: 10.1007/s00018-009-9154-y. View

14.

Coderoni S, Paparelli M, Gianfranceschi G . Phosphorylation sites for type N II protein kinase in DNA-topoisomerase I from calf thymus. Int J Biochem. 1990; 22(7):737-46. DOI: 10.1016/0020-711x(90)90009-r. View

15.

Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes J, Cochet C . Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer. 2007; 43(5):928-34. DOI: 10.1016/j.ejca.2006.11.021. View

16.

Bomgaars L, Berg S, Blaney S . The development of camptothecin analogs in childhood cancers. Oncologist. 2001; 6(6):506-16. DOI: 10.1634/theoncologist.6-6-506. View

17.

Larsen A, Skladanowski A . Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta. 1998; 1400(1-3):257-74. DOI: 10.1016/s0167-4781(98)00140-7. View

18.

Bandyopadhyay K, Gjerset R . Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. Biochemistry. 2010; 50(5):704-14. PMC: 3046806. DOI: 10.1021/bi101110e. View

19.

Sugimoto Y, Tsukahara S, Isoe T, Tsuruo T . Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 1990; 50(21):6925-30. View

20.

Karayan L, Riou J, SEITE P, Migeon J, Cantereau A, Larsen C . Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene. 2001; 20(7):836-48. DOI: 10.1038/sj.onc.1204170. View